These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21917382)

  • 1. Pharmacogenetics of anti-estrogen treatment of breast cancer.
    Del Re M; Michelucci A; Simi P; Danesi R
    Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in the research of pharmacogenomics of tamoxifen].
    Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
    Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of endocrine therapy for breast cancer.
    Higgins MJ; Stearns V
    Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
    Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
    Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
    Binkhorst L; Mathijssen RH; Jager A; van Gelder T
    Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
    Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
    Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.